Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)Adenocarcinoma of the StomachColorectal Cancer MetastaticNeuroendocrine Tumor (NET)
Interventions
DRUG

177Lu-CTR-FAPI nuclide-targeted therapy

Fasting, special diets, or other specific preparations are not required on the day of 177Lu-CTR-FAPI administration. Patients were given 4 mg ondansetron 30 minutes before treatment to prevent nausea and vomiting. The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi) was diluted with 100 mL of 0.9% saline and given slowly by intravenous infusion over 20-30 minutes (flow rate 200 ml/h). Symptoms and vital signs were monitored before and after treatment. The treatment regimen was planned for a maximum of 3 courses of treatment, with 4-8 weeks between each cycle

Trial Locations (1)

Unknown

Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an, Shaanxi Province Recruiting, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER